Role of RANKL inhibition in osteoporosis

Osteoporosis is a disorder of impaired bone strength that results in skeletal fragility and increased fracture risk

Michael McClung

2007

Scholarcy highlights

  • Osteoporosis is a disorder of impaired bone strength that results in skeletal fragility and increased fracture risk
  • The women were followed for 84 days to determine the effects of OPG therapy on urinary NTX and bone-specific alkaline phosphatase
  • No changes were noted in circulating numbers of white blood cells, T or B lymphocytes, immunoglobulins, or coagulation factors. Encouraged by these results, 412 postmenopausal women with low bone mineral density were enrolled in a phase II, randomized, doubleblind, placebo-controlled, dose-ranging trial conducted to determine the effect of denosumab on lumbar spine BMD
  • Additional studies will determine the effectiveness of denosumab in treating patients with osteoporosis induced by drug treatment, including glucocorticoid therapy, aromatase inhibitors, and inhibitors of gonadotropin secretion
  • Inhibiting RANK with its ligand with a highly specific antibody significantly affects bone metabolism and appears to be a promising treatment for osteoporosis and other bone diseases characterized by increased bone turnover
  • In addition to documenting and quantifying the efficacy of denosumab therapy in large numbers of patients, it will be important to monitor potential effects on the cardiovascular and immune systems

Need more features? Save interactive summary cards to your Scholarcy Library.